Testosterone levels start their slow descent around age 30, dropping roughly one to two percent annually. By the time many men hit their 50s or 60s, they feel like strangers in their own bodies , tired, irritable, foggy, less interested in sex than they used to be. It's a universal-enough story that testosterone replacement therapy (TRT) has become one of the most talked-about treatments in men's health. But behind the marketing hype and the enthusiasm of advocates lies a genuinely complicated medical debate about who actually needs it, what the science does and doesn't show, and what risks come with it.
A landmark feature in Nature this May pulled together the latest evidence, including major developments from an FDA advisory panel meeting in December 2025 that could reshape how the United States regulates testosterone entirely [1].
What Testosterone Actually Does
Testosterone is the primary male sex hormone, responsible for muscle mass, bone density, body hair, and sex drive. It also plays a role in mood, energy regulation, and cognitive function. The hormone binds to receptors throughout the body, influencing everything from red blood cell production to how men store fat.
A "normal" testosterone level typically falls between 350 and 750 nanograms per deciliter (ng/dL). When levels drop below 300 ng/dL, doctors generally classify that as low testosterone, or hypogonadism. For decades, the only FDA-approved indication for testosterone therapy was a specific condition called "classical hypogonadism" , which refers to men whose bodies simply do not produce adequate testosterone due to genetic disorders, pituitary damage, or injury to the testicles [1][5].
That narrow approval is about to change, potentially in a dramatic way.
The FDA Panel's Landmark Recommendation
In December 2025, an FDA advisory panel voted nearly unanimously to recommend sweeping changes to how testosterone is classified and prescribed. The panel called TRT "a cornerstone of preventive health" and described it as a "multibillion-dollar preventive-care opportunity" [1]. Those are extraordinary words from a regulatory body that has treated testosterone as a controlled substance for decades.
Specifically, the panel recommended removing testosterone's Schedule III status, expanding eligibility beyond men with classical hypogonadism, and dropping outdated warnings about prostate cancer risks that current evidence no longer supports [1][3]. Then in April 2026, the FDA took a concrete step forward, encouraging pharmaceutical sponsors to seek new indications for testosterone therapy [2].
This shift did not come out of nowhere. It follows the publication of the TRAVERSE trial, one of the largest and most rigorous studies ever conducted on testosterone therapy.
The TRAVERSE Trial: What It Found
The TRAVERSE trial enrolled 5,200 men with low testosterone and pre-existing cardiovascular risk factors , men who stood to be the most vulnerable if testosterone actually did increase heart risks [1][4]. The question that had haunted testosterone therapy for years was whether it raised the chances of heart attack or stroke. The answer from TRAVERSE was striking: there was no statistically significant increase in cardiovascular events compared to placebo [1][4].
Mohit Khera, a researcher at Baylor College of Medicine and a co-author of the TRAVERSE study, put it bluntly: "This study only picked very sick people, the greatest-risk population, and nothing bad happened to them" [1]. That is a remarkable result that has given both doctors and patients new confidence in the treatment's safety profile.
Beyond cardiovascular outcomes, TRAVERSE also tracked sexual function. Men receiving testosterone therapy reported a 25 percent greater increase in sexual activity compared to those on placebo [1]. The treatment also showed benefits in resolving hypogonadism symptoms for men whose levels genuinely fell below the threshold.
In February 2025, the FDA already removed the cardiovascular warning from testosterone product labeling, effectively acknowledging that the old fears were not borne out by the evidence [4].
Who Actually Qualifies Today
Even with the regulatory shifts underway, the medical community is still working through who should receive testosterone therapy and under what circumstances. Abraham Morgentaler, a urologist at Harvard Medical School who served on the December 2025 FDA panel, argues that the current system is far too restrictive. "You could make a very strong argument that having a normal testosterone level is important for health and prevention of illness," he told Nature [1]. His position is that more men with clinically low levels deserve access to treatment, not fewer.
The TRAVERSE data supports that view for men with genuinely low testosterone and symptoms. But the picture becomes more complicated when therapy extends beyond that group.
The Risks of High-Dose Use
Not all testosterone use is created equal. The medical establishment draws a sharp distinction between therapeutic replacement, restoring levels to a normal range, and supraphysiological dosing, which pushes levels far above what the body naturally produces.
At high doses, the risks are significant. Men can develop cardiomyopathy, a weakening of the heart muscle. Infertility becomes a serious concern because exogenous testosterone suppresses the body's own production, shrinking testicles and dramatically reducing sperm count. Erectile dysfunction can paradoxically worsen. Psychiatric effects including irritability and even psychosis have been documented [5].
A Danish study found that men using high doses of anabolic steroids had three times the mortality rate of non-users [1]. Channa Jayasena, a researcher at Imperial College London, offered a nuanced take: "For reasons we don't fully understand, very high doses of testosterone do something that therapeutic testosterone doesn't do" [1].
Dependence is another real concern. Approximately 30 percent of men on high-dose testosterone therapy become dependent on it, meaning their bodies stop producing any meaningful amount of natural testosterone and require ongoing external supplementation to function [1].
The Wellness Clinic Problem
Perhaps the most contentious issue in the testosterone debate is the proliferation of wellness clinics marketing TRT as a "lifestyle drug" to men with perfectly normal levels. These clinics often advertise energy, sharper focus, better workouts, and improved libido, benefits that healthy men with healthy testosterone levels would not realistically expect to gain [1][5].
Dr. Helen Bernie, a urologist at Indiana University, described the current regulatory reality bluntly: "Testosterone is still regulated as if it were a dangerous, performance-enhancing drug from the athletic doping scandals of the 1980s" [5]. She was speaking in the context of the gap between how the drug is classified and what the evidence actually shows about its risks at therapeutic doses.
That gap cuts both ways. For men with genuine hypogonadism, overcautious regulation has sometimes prevented access to a treatment that genuinely improves quality of life. For men with normal levels seeking a performance edge, the same relaxed environment could encourage use with no medical justification and real physiological consequences.
Where Things Stand Now
The FDA's April 2026 announcement signaled that the agency wants pharmaceutical companies to pursue new approved indications for testosterone therapy, a move that would effectively broaden access beyond classical hypogonadism [2]. The December 2025 panel recommendations, if enacted, would fundamentally restructure how testosterone is scheduled and prescribed [1][3].
For men wondering whether testosterone therapy is right for them, the honest answer is that it depends heavily on individual circumstances. Men with genuinely low levels and documented symptoms have the strongest case for treatment. Men with normal levels seeking performance or vitality gains from a wellness clinic are operating in territory that science does not support and that carries real physiological risks.
The next year or two will likely redefine what testosterone therapy looks like in America. Whether that ends up helping the men who need it most, or primarily serves those who want it most, may depend on how well the medical system communicates the evidence.